| data suggest that KLF6 is a tumor suppressor gene involved in human prostate cancer | prostate, |
| KLF6, a putative tumor suppressor gene, is mutated in astrocytic gliomas. | glioma, |
| Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer. | colorectal, |
| Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. | liver, |
| A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. | prostate, |
| Absence of mutation in the putative tumor-suppressor gene KLF6 in colorectal cancers. | colorectal, |
| E-cadherin pathway is a novel and functionally important mediator by which changes in Kruppel-like KLF6 tumor suppressor can directly alter ovarian tumor invasion and metastasis. | ovarian, |
| KLF6 gene may be one of the candidate tumor suppressor genes in colorectal cancers and that genetic alteration of the KLF6 gene might play a role in the development of colorectal carcinomas. | colorectal, |
| Inactivation of the tumor suppressor Kr??ppel-like factor 6 (KLF6) by mutation or decreased expression in hepatocellular carcinomas. | liver, |
| In vivo regulation of p21 by the Kruppel-like factor 6 tumor-suppressor gene in mouse liver and human hepatocellular carcinoma. | liver, |
| Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma. | glioblastoma, |
| variation at putative 8q24 cis-regulator(s) of transcription can significantly alter germline c-MYC expression levels and, thus, contribute to prostate cancer susceptibility by down-regulating the prostate tumor suppressor KLF6 gene. | prostate, |
| Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. | liver, |
| findings suggest an important role for the KLF6 tumour suppressor gene in gastric cancer development and progression and identify several highly cancer-relevant signalling pathways regulated by the KLF6 tumour suppressor gene. | gastric, |
| Pituitary tumor transforming gene 1 (PTTG1), an oncogene, was the most up-regulated transcript in KLF6+/- liver. PTTG1 downregulation represents a novel tumor suppressor pathway of KLF6. | liver,pituitary, |
| Nuclear expression of KLF6 tumor suppressor factor is highly associated with overexpression of ERBB2 oncoprotein in ductal breast carcinomas. | breast, |
| In melanoma cells, the tumor suppressor gene at 10p15 appears to be KLF6. Signaling from the collagen I-rich extracellular matrix appears to be involved in the tumor suppressive activity of KLF6 protein. | skin, |
| Energy restriction-mimetic agents induce apoptosis in prostate cancer cells in part through epigenetic activation of KLF6 tumor suppressor gene expression. | prostate, |
| Role of KLF6 tumor suppressor gene mutations in the development of colorectal carcinoma in an Egyptian population. | colorectal, |
| KLF6 deficiency contributes significantly to the carcinogenic milieu in human and murine HCC and uncover a novel tumor suppressor activity of KLF6 in HCC by linking its transcriptional repression of Mdm2 to stabilizing p53 | liver, |